Literature DB >> 1944609

Competitive antagonism by recognized 5-HT2 receptor antagonists at 5-HT1C receptors in pig choroid plexus.

I Sahin-Erdemli1, P Schoeffter, D Hoyer.   

Abstract

The effects of several antagonists, known to interact with 5-HT2 receptors (ritanserin, LY 53857, ICI 169,369, methysergide, mesulergine and ketanserin), were tested against 5-HT-stimulated production of inositol phosphate in pig choroid plexus, a 5-HT1C receptor model. These antagonists produced dextral shifts of the concentration response curve to 5-HT in a parallel manner, without depressing significantly the maximal response. The following pA2 values (in parentheses) were obtained: mesulergine (8.88), methysergide (8.85), LY 53857 (8.69), ritanserin (8.69), ICI 169,369 (7.86), and ketanserin (6.57). These pA2 values were in good agreement with the pKD values determined in radioligand binding studies performed in pig choroid plexus with [3H]mesulergine. The present data demonstrate that several drugs described as 5-HT2 receptor selective antagonists (e.g. ritanserin, LY 53857 and ICI 169,369) are also potent, competitive and surmountable antagonists at 5-HT1C receptors. Thus, the results provide further evidence for the pharmacological similarity of 5-HT1C and 5-HT2 receptors. However, in contrast to the situation described with methysergide, ritanserin and LY 53857 in several 5-HT2 receptor models, none of these antagonists acted in a non-competitive or unsurmountable fashion at 5-HT1C receptors. These results suggest, but do not firmly rule out, that at least in the presence of the drugs tested in the present study, 5-HT1C receptors in the choroid plexus do not undergo an allosteric modulation; these findings are apparently in contrast to a model proposed previously for 5-HT2 receptors (Kaumann and Frenken 1985, Naunyn-Schmiedeberg's Arch Pharmacol 328:295-300).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1944609     DOI: 10.1007/bf00167210

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

Review 1.  Molecular biology of 5-HT receptors.

Authors:  P R Hartig
Journal:  Trends Pharmacol Sci       Date:  1989-02       Impact factor: 14.819

2.  Allosteric properties of the 5-HT2 receptor system of the rat tail artery. Ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulators.

Authors:  M Frenken; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

3.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

4.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

5.  Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation.

Authors:  R A Bond; A G Ornstein; D E Clarke
Journal:  J Pharmacol Exp Ther       Date:  1989-05       Impact factor: 4.030

6.  5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization.

Authors:  D Hoyer; C Waeber; P Schoeffter; J M Palacios; A Dravid
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-03       Impact factor: 3.000

7.  Interaction of ketanserin and its metabolite ketanserinol with 5HT2 receptors in pulmonary and coronary arteries of calf.

Authors:  M Frenken; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

8.  A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptors.

Authors:  A J Kaumann; M Frenken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

9.  Dimethylation of the activator ICI 169,369 results in a high-affinity partial deactivator, ICI 170,809, of the arterial 5-hydroxytryptamine2 receptor system.

Authors:  M Frenken; A J Kaumann
Journal:  J Pharmacol Exp Ther       Date:  1989-08       Impact factor: 4.030

10.  Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites.

Authors:  D Hoyer; A Pazos; A Probst; J M Palacios
Journal:  Brain Res       Date:  1986-06-18       Impact factor: 3.252

View more
  5 in total

1.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis.

Authors:  D Fiorella; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

2.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. III: The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion.

Authors:  D Fiorella; S Helsley; D S Lorrain; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

3.  Characterization of functional responses in A9 cells transfected with cloned rat 5-HT1C receptors.

Authors:  H W Boddeke; B J Hoffman; J M Palacios; H Knot; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

4.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine.

Authors:  D Fiorella; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

5.  Hyperthermia induced by m-trifluoromethylphenylpiperazine (TFMPP) or m-chlorophenylpiperazine (m-CPP) in heat-adapted rats.

Authors:  A Kłodzińska; E Chojnacka-Wójcik
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.